Dual antiplatelet therapy and antithrombotic treatment: Recommendations and controversies

Cardiology Journal

Volumn 16, Issue 2, 2009, Pages 179-189

  Bryniarski, Leszek ^a   Pelc Nowicka, Agnieszka ^b   Zabojszcz, Michał ^a   Mirek Bryniarska, Ewa ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b J Dietl Hospital   (Poland)

Author keywords

Acetylsalicylic acid; Acute coronary syndromes; Antiplatelet therapy; Antithrombotic treatment; Atrial fibrillation; Clopidogrel; Oral anticoagulants

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN; FIBRINOLYTIC AGENT;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; EPISTAXIS; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMATOMA; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERNATIONAL NORMALIZED RATIO; LONG TERM CARE; MEDICAL SOCIETY; MITRAL VALVE REGURGITATION; MITRAL VALVE STENOSIS; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PULMONARY HYPERTENSION; RECOMMENDED DRUG DOSE; RETROPERITONEAL HEMORRHAGE; SIDE EFFECT; THROMBOSIS PREVENTION; TREATMENT DURATION; VEIN THROMBOSIS; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; DRUG COMBINATION; HEART VALVE REPLACEMENT; REVIEW; RISK ASSESSMENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; VALVULAR HEART DISEASE;

ACUTE CORONARY SYNDROME; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 66349132293     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (75)

1. Antman EM, Hand M, Armstrong PW et al. 2007 Focused Update of the ACC/ AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. Circulation, 2008; 117: 296-329.
2. Bassand JP, Hamm CW, Ardissino D et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J, 2007; 28: 1598-1660.
3. Silber S, Albertsson P, Fernandez-Avilès F et al. Guidelines for percutaneous coronary interventions. Eur Heart J, 2005; 26: 804-847.
4. Opolski G, Filipiak KJ, Poloński L. Ostre zespoły wieńcowe. Wyd. Med. Urban & Partner, Wrocław 2002.
5. ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE): A randomised controlled trial. Lancet, 2006; 367: 1903-1913.
6. Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. Ann Intern Med, 2007; 147: 590-592.
7. Schömig A, Neumann FJ, Kastrati A et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med, 1996; 334: 1084-1089.
8. Leon MB, Baim DS, Popma JJ et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med, 1998; 339: 1665-1671.
9. Ardissino D, Merlini PA, Ariëns R et al. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet, 1997; 349: 769-771.
10. Falk E. Unstable angina with fatal outcome: dynamic coronary thrombosis leading to infarction and/or sudden death. Autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation, 1985; 71: 699-708.
11. Davies MJ, Thomas AC, Knapman PA, Hangartner JR. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation, 1986; 73: 418-427.
12. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med, 1986; 315: 983-989.
13. The OASIS Investigators. Effects of long term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. J Am Coll Cardiol, 2001; 37: 475-484.
14. Fiore LD, Ezekowitz MD, Brophy MT et al. Department of Veterans Affairs Cooperative Studies Program Clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation, 2002; 105: 557-563.
15. Witte K, Thackray S, Clark AL, Cooklin M, Cleland JG. Clinical trials update: IMPROVEMENT-HF, COPERNICUS, MUSTIC, ASPECT-II, APRICOT and HEART. Eur J Heart Fail, 2000; 2: 455-460.
16. Hurlen M, Smith P, Arnsen H. Effects of warfarin, aspirin and the two combined, on mortality and thromboembolic morbidity after myocardial infarction. The WARRIS-II (Warfarin-Aspirin Reinfarction Study) design. Scand Cardiovasc J, 2000; 34: 168.
17. Cohen M, Adams C, Hawkins L, Bach M, Fuster V. Usefulness of antithrombotic therapy in resting angina pectoris or non-Q - wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the Antithrombotic Therapy in Acute Coronary Syndromes Study Group). Am J Cardiol, 1990; 66: 1287-1292.
18. Anand SS, Yusuf S, Pogue J, Weitz J, Flather M. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction. Circulation, 1998; 98: 1064-1070.
19. Cohen M, Adams C, Parry G et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Circulation, 1994; 89: 81-88.
20. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet, 1997; 350: 389-396.
21. Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low dose anticoagulation on obstructive changes in saphenous vein coronary artery bypass grafts. N Engl J Med, 1997; 336: 153-162.
22. Trip MD, Cats VM, van Capelle FJ, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med, 1990; 322: 1549-1554.
23. Merlini PA, Bauer KA, Oltrona L et al. Persistent activation of the coagulation mechanism in unstable angina and myocardial infarction. Circulation, 1994; 90: 61-68.
24. Flather MD, Weitz JI, Yusuf S et al. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractioned heparin in unstable angina myocardial infarction without ST elevation: Results of a randomized trial. OASIS Pilot Study Investigators. Eur Heart J, 2000; 21: 1473-1481.
25. Bertrand ME, Legrand V, Botand J et al. Randomized multicentre comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation, 1998; 98: 1597-1603.
26. Mehta SR, Yusuf S, Peters RJ et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet, 2001; 358: 527-533.
27. Rubboli A, Milandri M, Castelvetri C, Cosmi B. Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting. Cardiology, 2005; 104: 101-106.
28. King SB, Smith SC, Hirshfeld JW et al. 2007 focused update of the ACC/ AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol, 2008; 51: 172-209.
29. De Caterina R, Husted S, Wallentin L et al. Anticoagulants in heart disease: Current status and perspectives. Eur Heart J, 2007; 28: 880-913.
30. Luria HM, Knoke JD, Wachs JS et al. Survival after recovery from acute myocardial infarction: Two and five year prognostic indices. Am J Med, 1979; 67: 7-14.
31. Cristal N, Szwarcberg J, Gueron M. Supraventricular arrhythmias in acute myocardial infarction: Prognostic importance of clinical setting, mechanism of production. Ann Intern Med, 1975; 82: 35-39.
32. Helmers C, Lundman T, Mogenson I et al. Atrial fibrillation in acute myocardial infarction. Acta Med Scand, 1973; 193: 39-44.
33. Behar S, Zahavi Z, Goldbourt U et al. Long term prognosis of patients with paroxysmal atrial fibrillation complicating acute myocardial infarction. Eur Heart J, 1992; 13: 45-50.
34. Goldberg J, Seeley D, Becker RC et al. Impact of atrial fibrillation on the in-hospital and long term survival of patients with acute myocardial infarction: A community-wide perspective. Am Heart J, 1990; 119: 996-1001.
35. Julian D, Valentine P, Miller G. Disturbances of rate, rhythm and conduction in acute myocardial infarction. Am J Med, 1964; 37: 915-927.
36. Cristal N, Peterburg I, Szwarcberg J. Atrial fibrillation developing in the acute phase of myocardial infarction. Chest, 1976; 70: 8-11.
37. Crenshaw BS, Ward SR, Granger CB et al. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol, 1997; 30: 406-413.
38. Eldar M, Canetti M, Rotstein Z et al. for the SPRINT and Thrombolytic Survey Groups. Significance of paroxysmal atrial fibrillation complicating acute myocardial infarction in the thrombolytic era. Circulation, 1998; 97: 965-970.
39. Goldberg RJ, Yarzebski J, Lessard D, Wu J, Gore JM. Recent trends in the incidence rates of and death rates from atrial fibrillation complicating initial acute myocardial infarction: A community-wide perspective. Am Heart J, 2002; 143: 519-527.
40. Kinjo K, Sato H, Ohnishi Y et al. Prognostic significance of atrial fibrillation/atrial flutter in patients with myocardial infarction treated with percutaneous coronary intervention. Am J Cardiol, 2003; 92: 1150-1154.
41. Wong CK, White HD, Wilcox RG et al. Significance of atrial fibrillation during acute myocardial infarction, and its current management: Insights from the GUSTO-3 trial. Card Electrophysiol Rev, 2003; 7: 201-207.
42. Lehto M, Snapinn S, Dickstein K, Swedberg K, Nieminen MS. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: The OPTIMAL experience. Eur Heart J, 2005; 26: 350-356.
43. Lip GY, Karpha M. Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: The need for consensus and a management guideline. Chest, 2006; 130: 1823-1827.
44. Karjalainen PP, Porela P, Ylitalo A et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J, 2007; 28: 726-732.
45. Valencia J, Mainar V, Bordes P et al. Observance of antiplatelet therapy after stent implantation in patients under chronic oral anticoagulant treatment. J Interv Cardiol, 2008; 21: 218-224.
46. Ruiz-Nodar JM, Marín F, Hurtado JA et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation: Implications for bleeding risk and prognosis. J Am Coll Cardiol, 2008; 51: 818-825.
47. Stenestrand U, Lindbäck J, Wallentin L, RIKS-HIA Registry. Anticoagulation therapy in atrial fibrillation in combination with acute myocardial infarction influences long-term outcome: A prospective cohort study from the register of information and knowledge about swedish haeart intensive care admissions (RIKS-HIA). Circulation, 2005; 112: 3225-3231.
48. Oudot A, Steg PG, Danchin N et al. Impact of chronic oral anti-coagulation on management and outcomes of patients with acute myocardial infarction: Data from the RICO survey. Heart, 2006; 92: 1077-1083.
49. Rao SV, Eikelboom JA, Granger CB et al. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J, 2007; 28: 1193-1204.
50. Ferguson JJ, Califf RM, Antman EM et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: Primary results of the SYNERGY randomized trial. JAMA, 2004; 292: 45-54.
51. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: A randomised trial. Lancet, 1999; 353: 429-438.
52. PRISM Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med, 1998; 338: 1498-1505.
53. Moscucci M, Fox KA, Cannon CP et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J, 2003; 24: 1815-1823.
54. Alexander KP, Chen AY, Roe MT et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA, 2005; 294: 3108-3116.
55. Flaker GC, Gruber M, Connolly SJ et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J, 2006; 152: 967-973.
56. Mattichack SJ, Reed PS, Gallagher MJ et al. Evaluation of safety of warfarin in combination with antiplatelet therapy for patients treated with coronary stents for acute myocardial infarction. J Interv Cardiol, 2005; 18: 163-166.
57. Khurram Z, Chou E, Minutello R et al. Combination therapy with aspirin, clopidogrel and warfarin following coronary stenting is associated with a significant risk of bleeding. J Invasive Cardiol, 2006; 18: 162-164.
58. Konstantino Y, Iakobishivili Z, Porter A et al. Aspirin, warfarin and a thienopyridine for acute coronary syndromes. Cardiology, 2006; 105: 80.
59. Orford JL, Fasseas P, Melby S et al. Safety and efficacy of aspirin, clopidorel, and warfarin after coronary stent placement in patients with an indication for anticoagulation. Am Haert J, 2004; 147: 463.
60. DeEugenio D, Kolman L, DeCaro M et al. Risk of major bleeding with concomitant dual antiplatelet therapy after percutaneous coronary intervention in patients receiving long-term warfarin therapy. Pharmacotherapy, 2007; 27: 691-696.
61. Rubboli A, Colletta M, Sangiorgio P, Di Pasquale G. Antithrombotic strategies in patients with an indication for long-term anti-coagulation undergoing coronary artery stenting: safety and efficacy data from a single center. Ital Heart J, 2004; 5: 919-925.
62. Urban P, Macaya C, Rupprecht HJ et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicentre aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation, 1998; 98: 2126-2132.
63. Buresly K, Eisenberg MJ, Zhang X, Pilote L. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med, 2005; 165: 784-789.
64. Zawilska K, Brozek J, Jaeschke R et al. Wytyczne profilaktyki i leczenia żylnej choroby zakrzepowo-zatorowej: Aktualizacja 2005. Med. Prakt, 2005; 6: supl.
65. Fuster V, Ryden LE, Cannom DS et al. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation. J Am Coll Cardiol, 2006; 48: 149-246.
66. Salem DM, Stein PD, Al-Ahmad A et al. Antithrombotic Therapy in Valvular Heart Disease - Native and Prosthetic: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004; 126: 457S-482S.
67. Butchart EG, Gohlke-Bärwolf C, Antunes MJ et al. Recommendations for the management of patients after heart valve surgery. Eur Heart J, 2005; 26: 2463-2471.
68. Bonow RO, Carabello BA, Chatterjee K et al. ACC/AHA 2006 Guidelines for the management of patients with valvular heart disease: a report of American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2006; 48: 598.
69. Vahanian A, Baumgartner H, Bax J et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J, 2007; 28: 230-268.
70. Galie N, Torbicki A, Barst A et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J, 2004; 25: 2243-2278.
71. Sacco RL, Adams R, Albers G et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: A statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke, co-sponsored by the Council on Cardiovascular Radiology and Intervention. Stroke, 2006; 37: 577-617.
72. Hall P, Nakamura S, Maiello L et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation, 1996; 93: 215-222.
73. Berger PB, Steinhubl S. Clinical Implications of Percutaneous Coronary Intervention-Clopidogrel in Unstable angina to prevent Recurrent Events (PCI-CURE) Study: A US Perspective. Circulation, 2002; 106: 2284-2287.
74. Beinart SC, Kolm P, Veledar E et al. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention: Results from the Clopidogrel for the Reduction of Events During Observation (CREDO) Trial. J Am Coll Cardiol, 2005; 46: 761.
75. Becker RC, Meade TW, Berger PB e al. Antithrombotic and thrombolytic therapy. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. 8th Ed. Chest, 2008; 133: 776S-814S.